EKF Diagnostics (OTCMKTS:EKDHF – Get Free Report) is projected to announce its resultson Tuesday, September 15th. Analysts expect EKF Diagnostics to announce earnings of $0.0119 per share and revenue of $33.1420 million for the quarter.
EKF Diagnostics Price Performance
OTCMKTS:EKDHF opened at $0.34 on Friday. The business’s 50-day moving average is $0.34 and its two-hundred day moving average is $0.34. EKF Diagnostics has a 12 month low of $0.29 and a 12 month high of $0.42.
EKF Diagnostics Company Profile
EKF Diagnostics Holdings plc (OTCMKTS: EKDHF) is a global in vitro diagnostics company that develops, manufactures and markets a broad range of point-of-care and laboratory analyzers, reagents and consumables. The company’s product portfolio addresses key segments of the diagnostic testing market, including haematology, biochemistry, immunoassay, haemostasis and diabetes monitoring.
EKF Diagnostics offers peripheral blood analyzers designed for use in clinical laboratories, hospitals and veterinary clinics, along with handheld and benchtop devices for rapid on-site testing.
Further Reading
- Five stocks we like better than EKF Diagnostics
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
